Lysergide d-tartrate (MM120) is an investigational new drug that was granted breakthrough therapy status for the treatment of Generalized Anxiety Disorder by the FDA in March 2024.[1] It is a salt of lysergide.[2][3]
Identifiers | |
---|---|
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H31N3O7 |
Molar mass | 473.526 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Meara K (7 March 2024). "FDA Grants Breakthrough Therapy Designation to LSD-Based Treatment for Generalized Anxiety Disorder". Drug Topics. Drug Topics April 2024. 168. Retrieved 8 March 2024.
- ^ Grinstein JD (14 April 2023). "Licit Activity: MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder". GEN - Genetic Engineering and Biotechnology News. Retrieved 8 March 2024.
- ^ LaMotte S (7 March 2024). "Single dose of LSD provides immediate, lasting anxiety relief, study says". CNN. Retrieved 8 March 2024.